<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689494</url>
  </required_header>
  <id_info>
    <org_study_id>BnaiZionMC-08-BP-003-CTIL</org_study_id>
    <nct_id>NCT00689494</nct_id>
  </id_info>
  <brief_title>Cervical Device Contraception-2 (Nanopaz)</brief_title>
  <acronym>NANOPAZ</acronym>
  <official_title>Cervical Device Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measure blood progesterone by using cervical device contraception.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A very small cervical device that releases small amount of progesterone 20 mcgm/day.

      The target of the research is to measure blood progesterone by using the cervical device.

      This small device delivers progesterone by nanotechnology method.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood progesterone measure in blood</measure>
    <time_frame>one to two months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nanopaz contraception device</intervention_name>
    <description>levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method</description>
    <other_name>levonorgestrel device for cervical contraception-nantechnolgy method</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  10 healthy women are candidate for hysterectomy

        Exclusion Criteria:

          -  Women with neoplastic malignancy disease or thrombophylia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>June 2, 2008</last_update_submitted>
  <last_update_submitted_qc>June 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Baram Paz</name_title>
    <organization>Bnai Zion MC</organization>
  </responsible_party>
  <keyword>Nanopaz device</keyword>
  <keyword>Blood progesterone measure in using the device</keyword>
  <keyword>Delivery progesterone</keyword>
  <keyword>Progesterone levonorgestrel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

